Aims and Scope of Human Vaccines and Immunotherapeutics
Human Vaccines & Immunotherapeutics is a monthly peer-reviewed medical journal covering research into vaccines and immunotherapeutics in humans. It was established in 2005 as Human Vaccines, and obtained its current name in 2012. It is published by Taylor & Francis and the editor-in-chief is Ronald Ellis (FutuRx). According to the Journal Citation Reports, the journal had a 2013 impact factor of 3.643. Less
Key Metrics
CiteScore 

5.5
H-Index 

80
Impact Factor 

< 5
Scite Index 

0.83 5-Year SI

SJR 

Q1Immunology

SNIP 

1.36
Recommended pre-submission checks
Powered by 

Topics Covered on Human Vaccines and Immunotherapeutics
Human Vaccines and Immunotherapeutics Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS INC |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | EUR 2895 | GBP 2495 | USD 3175 |
| Publication Time | 11 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | International Society for Vaccines (ISV) |
| Frequency | Monthly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Human Vaccines and Immunotherapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Human Vaccines and Immunotherapeutics
The importance of first-void urine for assessing HPV-specific antibodies: A comparison with midstream urine
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Antibody levels and immune memory in children with kaposiform hemangioendothelioma treated with sirolimus after catch up vaccination
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Vaccination in systemic lupus erythematosus
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Nursing students’ knowledge and attitudes toward human papillomavirus vaccination and infection
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Parents’ perceived safety, usability, and acceptability of vaccination through microarray patches: A preliminary multi-national cross-sectional survey
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
The importance of first-void urine for assessing HPV-specific antibodies: A comparison with midstream urine
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Antibody levels and immune memory in children with kaposiform hemangioendothelioma treated with sirolimus after catch up vaccination
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Vaccination in systemic lupus erythematosus
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Nursing students’ knowledge and attitudes toward human papillomavirus vaccination and infection
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics
Parents’ perceived safety, usability, and acceptability of vaccination through microarray patches: A preliminary multi-national cross-sectional survey
- 31 Dec 2026
- Human Vaccines & Immunotherapeutics